REG - Tissue Regenix Group - Result of AGM

Tissue RegenixAnnouncement

25/04/2024 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240425:nRSY0853Ma&default-theme=true

RNS Number : 0853M  Tissue Regenix Group PLC  25 April 2024

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

 

Result of Annual General Meeting

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company,
announces that at the Annual General Meeting ('AGM') held earlier today, all
resolutions were duly passed on a show of hands.

 

The results of the proxy votes received in respect of the resolutions, given
to the Chair prior to the meeting, are set out below:

 

 Resolution            In favour   %      Against  %     Withheld
 1           Ordinary  30,257,029  99.99  610      0.01  12,274
 2           Ordinary  30,249,468  99.98  7,296    0.02  13,149
 3           Ordinary  30,254,468  99.99  2,296    0.01  13,149
 4           Ordinary  30,254,468  99.99  2,296    0.01  13,149
 5           Ordinary  30,254,968  99.99  1,796    0.01  13,149
 6           Ordinary  30,254,468  99.99  2,296    0.01  13,149
 7           Ordinary  30,254,468  99.99  2,296    0.01  13,149
 8           Ordinary  30,255,203  99.99  1,561    0.01  13,149
 9           Ordinary  30,255,203  99.99  2,436    0.01  12,274
 10          Ordinary  30,253,968  99.96  11,671   0.04  4,274
 11          Special   30,049,183  99.28  216,456  0.71  4,274
 12          Special   30,236,441  99.93  21,198   0.07  12,274

 

 

Notes:

1.     A "Vote withheld" is not counted in the calculation of the
percentage of shares voted "In favour" or "Against".

2.     As at 23 April 2023, being the voting deadline date in respect of
the Annual General Meeting, the total number of Ordinary Shares of 0.1p each
in issue and the total number of voting rights was 70,574,468.

 

The full text of the resolutions passed at the AGM may be found in the Notice
of AGM published on 19 March 2024.

 

For more information:

 

 Tissue Regenix Group plc                                                www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                                    via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)   Tel: +44 (0)20 7933 8780
 Alice Woodings/Charlotte Edgar      TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries, and
wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEMFDIELSEEL